BIBLIOGRAPHY - THOMAS A. BAN, M.D.

1. Ban, Tamás

2. Ban, Tamás and Balázs, Bela

3. Ban, Tamás (Book Review)

4. Ban, Tamás

5. Ban, Thomas A.

6. Ban, T.A. and Schwarz, L.

7. Ban, T. and Kerenyi, N.


11. Schwarz, L., Ban, T. and Smith, R.


14. Ban, T.A. and St.Laurent, J.

15. Ban, T.A. and St.Laurent, J.

16. Ban, T.A.

17. Levy, L., and Ban, T.

18. St.Laurent, J., Cahn, C. and Ban, T.A.


29. St.Jean, A., Donald, M.W. and Ban, T.A.  

30. Ban, T.A. and Schwarz, L.  

31. Ban, T.A.  

32. St.Jean, A., Donald, M.W. and Ban, T.A.  

33. Lehmann, H.E. and Ban, T.A.  

34. Cameron, D.E., Levy, L., Ban, T.A. and Rubenstein, L.  


36. Lehmann, H.E. and Ban, T.A.  

37. Ban, T.A. and Kerenyi, N.  
38. St.Jean, A., Donald, M.W. and Ban, T.A.
   Interchangeability of antiparkinsonian medication.

39. Ban, T.A. (Book Review)

40. Ban, T.A., St.Jean, A. and Desautels, S.
   The effects of phenothiazines on the human
   electrocardiogram. In: Bente, D. and Bradley, P.B.
   (eds.): Neuropsychopharmacology. Vol. 4. Elsevier,
   Amsterdam.

41. Ban, T.A. et St.Jean, A.
   Contribution de praticien general au traitement de la
   schizophrenia. Bulletin de Centre de Psychiatrie et

42. Ban, T.A.
   Conditioning and Psychiatry. Aldine Publishing

   Discromias cutaneas y alteraciones oculares
   observadas en el tratamiento prolongado con la

44. Matthews, V., Lehmann, H.E. and Ban, T.A.
   A comparative study of thirteen hypnotic drugs.

45. Lehmann, H.E. and Ban, T.A. (eds.)

   The psychophysical effects of butyrophenones in male
   schizophrenics. In: Lehmann, H.E. and Ban, T.A.
   (eds.): The Butyrophenone in Psychiatry. Quebec
   Psychopharmacological Research Association,
   Montreal, 1964.
47. Lehmann, H.E., Ban, T.A., Matthews, V. and Garcia-Rill, T.

48. Warnes, H., Lee, H. and Ban, T.A.

49. Ban, T.A. and Stonehill, E.

50. Ban, T.A.

51. Ban, T.A.

52. Ban, T.A.

53. Ban, T.A., Lehmann, H.E., Matthews, V. and Donald, M.

55. Ban, T.A.

56. Ban, T.A. and Lehmann, H.E.

57. Lehmann, H.E., Berthiaume, M. and Ban, T.A. (eds.)

58. St. Jean, A., Ban, T.A. and Noe, W.

59. Erutku, I., Ban, T.A. and Lehmann, H.E.


61. Ban, T.A.

62. Lehmann, H.E. and Ban, T.A.
63. Lehmann, H.E., Ban, T.A. and Donald, M. 
   Rating the rater. Archives of General Psychiatry, 

64. St. Jean, A., Csonba, T., Noe, W. and Ban, T.A. 
   Human pharmacology and progressive clinical 
   screening of a new psychoactive compound (Ciba 30, 

65. Levy, L., Cameron, E. D., Ban, T.A. and Rubenstein, L. 
   The effects of long-term repetition of verbal 
   1965.

66. Ban, T.A. (Book Review) 
   "The Action of Neuroleptic Drugs: A Psychiatric, 
   Neurologic and Pharmacological Investigation." 

67. St. Jean, A., Farladeau, S. L. and Ban, T.A. 
   Use of xanthine niacinate with geriatric patients. 

68. Ban, T.A. and St. Jean, A. 
   Electrocardiographic changes induced by 
   phenothiazine drugs. American Heart J., 70:575-576, 
   1965.

69. Ban, T.A. (Book Review) 

70. St. Jean, A., Ban, T.A. and Noe, W. 
   Psychopharmacological studies with Noserpe and 

71. Lehmann, H.E., Gallai, A. and Ban, T.A. 
   Pigmentation de la peau: consecutif a 
   l'administration prolongee de fortes doses de 

72. Ban, T.A., St. Jean, A. and Desautels, S. 
   The effects of phenothiazine on the human electro-
   cardiogram. In Bente, D. and Bradley, P. B. (eds.): 
   Neuropsychopharma-cology. Vol. 4. Elsevier, 
   Amsterdam, 1965.
73. Ban, T.A.  


75. Ban, T.A.  

76. Roy, P., St. Jean, A., Ban, T.A. and Noe, W.  

77. Choi, S. M., Ban, T.A., Lehmann, H.E. and Adamo, E.  


80. St. Jean, A., Ban, T.A. and Noe, W.  

81. Ban, T.A. (Book Review)  

82. Ban, T.A.  

84. Ban, T.A.  
What pre-clinical information does the clinician expect to be given prior to conducting trials with a new drug? Bulletin of the American College of Neuropsychopharmacology, 4:8, 1966.

85. Ban, T.A. and Lehmann, H.E.  

86. Ban, T.A.  

87. Stonehill, E., Lee, H. and Ban, T.A.  

88. Ban, T.A.  

89. Ban, T.A.  

90. Ban, T.A.  


93. Roy, P.B., Ferguson, K., St. Jean, A., Lee, H. and Ban, T.A.  


95. Lehmann, H.E., Ban, T.A. and Lee, H.  

96. Hatangadi, S., Lidsky, A. and Ban, T.A.  

97. Ban, T.A.  

98. Lehmann, H.E. and Ban, T.A.  
The nature and frequency of the suicide syndrome, twenty years ago and today, in the English-speaking community of the Province of Quebec. Laval medical, 38:93-95, 1967.

99. Ban, T.A.  

100. Lehmann, H.E., Ban, T.A. and Naltchayan, E.  

101. Warnes, H., Lehmann, H.E. and Ban, T.A.  

103. Ferguson, K., Ban, T.A., Lehmann, H.E. and Lee, H
Etude comparative de la propercizaine dans le
controle du comportement antisocial. L'Union Med.

104. Ban, T.A. (Book Review)
"Depressive States: A Pharmacotherapeutic Study."

105. Ban, T.A.
Clinical pharmacology of psychotropic drugs. Appl.

106. Warnes, H., Lehmann, H.E. and Ban, T.A.
Adynamic ileus during psychoactive medication. Can.

A clinical pharmacological study with EXP 561.

108. Lehmann, H.E. and Ban, T.A.
Comparative pharmacotherapy of the aging psychiatric

109. Lehmann, H.E. and Ban, T.A.
Chemical reduction of the compulsion to drink with
metronidazole: a new treatment modality in the
therapeutic program of the alcoholic. Curr. Ther.

110. Ban, T.A.
Clinical pharmacology of psychotropic drugs: Part
II - the benzodiazepines. Appl. Ther., 2:677-680,
1967.

111. St. Jean, A., Sterlin, C., Noe, W. and Ban, T.A.
Clinical studies with propercizaine (R.P. 8909).

112. Ban, T.A. and Lehmann, H.E.
Efficacy of haloperidol in drug refractory patients.
International Journal of Neuropsychiatry, 3:S79-S86,
1967.

113. Oliveros, R. F., Amin, M., Ban, T.A. and Lehmann, H.E.
A clinical trial of thiothixene (Navane) in
114. Ban, T.A.

115. Kristof, F.E., Lehmann, H.E. and Ban, T.A.


119. Ban, T.A.

120. Ban, T.A. (Book Review)

121. Lehmann, H.E. and Ban, T.A.

122. Amin, M., Lehmann, H.E. and Ban, T.A.


124. Ban, T.A. (Book Review)
125. Beaubien, J., Kristof, F. E., Lehmann, H.E. and Ban, T.A.

126. Lehmann, H.E. and Ban, T.A. (eds.)
Toxicity and Adverse Reaction Studies With Neuroleptics and Antidepressants. Quebec Psychopharmacological Research Association, Montreal, 1968.

127. Lehmann, H.E. and Ban, T.A.

128. Ban, T.A.

129. Lee, H., Lehmann, H.E. and Ban, T.A.

130. St. Jean, A., Desautels, S., Ballon, J. and Ban, T.A.

131. St. Jean, A. and Ban, T.A.

133. Lehmann, H.E. and Ban, T.A.  


135. Hattangadi, S., Lidsky, A., Lee, H. and Ban, T.A.  

136. Lehmann, H.E. and Ban, T.A.  

137. Sterlin, C., Lehmann, H.E., Oliveros, R.F., Ban, T.A. and Saxena, B.M.  


139. Sterlin, C., Oliveros, R.F. and Ban, T.A.  

140. Ban, T.A. (Book Review)  

141. Lehmann, H.E. and Ban, T.A. (eds.)  
142. Lehmann, H.E. and Ban, T.A.

143. Warnes, H., Canfield, J. and Ban, T.A.

144. Ban, T.A.

145. Ban, T.A.

146. Ban, T.A.

147. Lehmann, H.E. and Ban, T.A.


149. Ban, T.A., Lehmann, H.E. and Green, A.A.

150. Silver, D., Ban, T.A., Kristof, F.E., Saxena, B.M., and Bennett, Jean

151. Silver, D., Beaubien, J., Ban, T.A., Saxena, B.M., and Bennett, Jean
152. Ban, T.A.
Niacin in the treatment of schizophrenia.

153. Ban, T.A., Lehmann, H.E. and Green, A.A.

154. Lehmann, H.E. and Ban, T.A.

155. Ananth, J.V., Ban, T.A., Lehmann, H.E. and Bennett, Jean

156. Sterlin, C., Ban, T.A., Lehmann, H.E. and Saxena, B.M.


159. Ananth, J.V., Ban, T.A. and Lehmann, H.E.

160. Lehmann, H.E. and Ban, T.A.
161. Oliveros, R.T., Ban, T.A., Lehmann, H.E., Sterlin, C. and Saxena, B.M.

162. Lehmann, H.E. and Ban, T.A.


164. Beaubien, J., Ban, T.A., Lehmann, H.E. and Jarrold, Louise

165. Sterlin, C., Ban, T.A., Lehmann, H.E. and Jarrold, Louise

166. Ramsay, R.A., Ban, T.A., Lehmann, H.E., Saxena, B.M. and Bennett, Jean

167. Guttman, H., Lehmann, H.E. and Ban, T.A.

168. Ananth, J.V., Lehmann, H.E. and Ban, T.A.

169. Lehmann, H.E., Black, P. and Ban, T.A.
170. Ban, T.A., Lehmann, H.E. and Green, A.A.

171. Sterlin, C., Ban, T.A., Lehmann, H.E. and Saxena, B.M.

172. Ban, T.A., Lehmann, H.E. and Saxena, B.M.


175. Chouinard, G., Lehmann, H.E. and Ban, T.A.


178. Lehmann, H.E., Ban, T.A. and Saxena, B.M.

179. Ban, T.A.
180. Ananth, J.V., Lehmann, H.E. and Ban, T.A.
Toxic psychosis induced by benzhexol hydrochloride.

181. Ban, T.A. (Book Review)

182. Ban, T.A. and Lehmann, H.E.
Nicotinic acid in the treatment of schizophrenias.
1970.

183. Lehmann, H.E. and Ban, T.A.
Pharmacotherapy of Tension and Anxiety. Charles C.

Tolbutamide jaundice associated with multiple drug

185. Vacaflor, L., Lehmann, H.E. and Ban, T.A.
Side effects and teratogenicity of lithium carbonate

186. Deutsch, M., Saxena, B.M., Lehmann, H.E. and Ban, T.A.
Combined administration of thioridazine and
fluoxymesterone in the treatment of geriatric

187. Ban, T.A.
Discussion of outpatient considerations.

188. Ban, T.A. and Lehmann, H.E.
Nicotinic acid in the treatment of schizophrenia: A

189. Ban, T.A.
Some double binds of clinical psychopharmacology: A

190. Lehmann, H.E., Ananth, J.V., Gaegea, K. and Ban, T.A.
Treatment of depression with Dexedrine and Demerol.

191. Sterlin, C., Augustin, E., Ban, T.A. and Jarrold, Louise
Doxepin as adjuvant medication in the treatment of
chronic schizophrenic patients: A comparative study.
192. Ban, T.A.

193. Ban, T.A. (Book Review)


197. Ban, T.A. and Lehmann, H.E.

198. Ananth, J.V., Deutsch, M. and Ban, T.A.


200. deVerteuil, R., Lehmann, H.E., Ban, T.A. and Saxena, B.M.

Test retest reliability in a conditioning test battery in normal and chronic schizophrenics. In:

203. Deutsch, M., Ananth, J.V. and Ban, T.A.
1971.

204. Ananth, J.V., Lajoie, R., Ban, T.A. and Lehmann, H.E.

205. Ban, T.A. (Book Review)

206. Káto, L., Gózsy, B., Ban, T.A. and Sterlin, C.
Effects of psychoactive agents on the conditioning of the microcirculation in the rat. Conditional

207. Biollat, Joyce E., Saxena, B.M., Lehmann, H.E. and Ban, T.A.
Combined administration of thioridazine, nicotinic acid and fluoxymesterone in the treatment of

208. Saxena, B.M., Lehmann, H.E. and Ban, T.A.
A systematic study with nicotinic acid, thioridazine, fluoxymesterone and their combinations in
hospitalized geriatric patients - therapeutic results and changes in psychometric test

209. Ban, T.A.
Nicotinic Acid in the Treatment of Schizophrenias:
Introduction to Canadian Mental Health Association
Collaborative Study. Canadian Mental Health

210. Ban, T.A.
Nicotinic Acid in the Treatment of Schizophrenias.
Complementary Report A. Canadian Mental Health
211. Ban, T.A.


213. Ban, T.A.

214. Ban, T.A.

215. Sterlin, C., Oliveros, R., Ban, T.A. and Jarrold, Louise


219. Ban, T.A.

220. Ban, T.A.

221. Ban, T.A.
222. Lehmann, H.E. and Ban, T.A.
Conditional reflex studies in the schizophrenias.

223. Lehmann, H.E. and Ban, T.A.
Effects of psychoactive drugs on conflict avoidance
behavior in human subjects. Activitas Nervosa

224. Ban, T.A. (Book Review)
"Discoveries in Biological Psychiatry." Amer. J.

225. Ban, T.A.
Methodological problems in the clinical evaluation
of anxiolytic drugs. In: Vinar, O., Votava, Z. and
Bradley, P.B. (eds.): Advances in
Neuropsychopharmacology. North-Holland Publishing

226. Ban, T.A.
Canadian Niacin Study - II. Schizophrenia Bull.,

227. Papathomopoulos, E. and Ban, T.A.
Symbiotic relationship of two chronic psychotic
patients: A clinical experimental study.

The use of methyldopa in schizophrenia: A review and
comparative study. Amer. J. Psychiat., 128:1207-
1211, 1972.

229. Sterlin, C., Ban, T.A. and Jarrold, Louise
The place of doxepin among the anxiolytic-sedative

230. Sterlin, C., Ban, T.A. and Jarrold, Louise
The place of thiothixene among the thioxanthenes.

231. Ban, T.A.
La practica psiquiatrica y la psicofarmacologia en
la decade de los anos 70. Revista Psiquiatrica
232. Ananth, J.V., Vacaflor, L., Kekhwa, G., Sterlin, C. and Ban, T.A.


234. Ananth, J.V., Salib, M., Ban, T.A. and Lehmann, H.E.


236. Ban, T.A.


239. Ban, T.A.

240. Lehmann, H.E., Ban, T.A. and Saxena, B.M.

241. Ban, T.A.


244. Klingner, A., Ban, T.A. and Lehmann, H.E.

245. Lehmann, H.E., Ban, T.A. and Saxena, B.M.


247. Sterlin, C., Ban, T.A. and Jarrold, Louise (Abstract)

248. Ban, T.A.


250. Lehmann, H.E. and Ban, T.A.


256. Ban, T.A.

257. Lipton, M.A. and Ban, T.A.


259. Ban, T.A.

260. Ban, T.A., Lehmann, H.E. and Green, A.A.
261. Sterlin, C., Ban, T.A. and Saxena, B.M. 


263. Lehmann, H.E., Ban, T.A. and Ananth, J.V. 

264. Ban, T.A. 

265. Lipton, M., Ban, T.A., Kane, F.J., Levine, J. and Wittenborn, J.R. 


270. Ban, T.A. and Lehmann, H.E.

271. Ban, T.A.

272. Ban, T.A. and Lehmann, H.E.

273. Nair, N.P.V., Ban, T.A., Hontela, S. and Clark, R.

274. Galvan, L., Nair, N.P.V., Kussin, D. and Ban, T.A.

275. Amin, M.M., Ban, T.A. and Klingner, A.

277. Ban, T.A. and Lehmann, H.E.

278. Ban, T.A.


282. Galvan, L., Ucha, R., Vergara, L., Zoch, C. and Ban, T.A.

284. Lehmann, H.E. and Ban, T.A.
Sex differences in long-term adverse effects of
pheno-thiazines. In: Forrest, I.S., Carr, C.J. and
Usdin, E. (eds.): Phenothiazines and Structurally

285. Lehmann, H.E. and Ban, T.A.
Thiotoxihene and the thioxanthenes. In: Forrest,
I.S., Carr, C.J. and Usdin, E. (eds.): Phenothia-
zines and Structurally Related Drugs. Raven

Conditioning in the prediction of drug withdrawal
effects in chronic schizophrenic patients.

287. Ban, T.A., Lehmann, H.E., Amin, M., Galvan, L., Nair, N.P.V.,
Vergara, L. and Zoch, C.
Systematic clinical studies with trazodone.

288. Ban, T.A. and Silvistrini B. (eds.)
Trazodone. Modern Problems of Pharmacopsychiatry.

289. Ban, T.A., Amin, M., Nair, N.P.V. and Engelsman, F.
Comprehensive clinical studies with trazodone in
Canada. In: Ban, T.A. and Silvistrini B. (eds.):
Trazodone. Modern Problems of Pharmacopsychiatry.

New drug developments in the Latin Americas. Dis.

Climan, M.
A transcultural study with clomacran. Comparison of
989, 1974.

292. Ban, T.A.
Depression and the Tricyclic Antidepressants.
Ronalds, Montreal, 1974.

293. Ban, T.A.
Negative findings with nicotinic acid in the
treatment of schizophrenias. Int. J.
294. Ban, T.A.

295. Ban, T.A.


297. Ban, T.A.

298. Ban, T.A.

299. Ban, T.A. and Lehmann, H.E.

300. Lehmann, H.E., Ban, T.A. and Schwartz, G.V.

301. Klingner, A., Ban, T.A. and Lehmann, H.E.


304. Ban, T.A.

305. Lehmann, H.E., Ananth, J.V., Gaegear, K.C. and Ban, T.A.
Treatment of depression with Dexedrine and Demerol.
In: Klein, D.F. and Gittelman-Klein, Rachel (eds.):
Progress in Psychiatric Treatment. Brunner/Mazel,

306. Lehmann, H.E., Ban, T.A. and Saxena, B.M.
Nicotinic acid, thioridazine, fluoxymesterone and
their combinations in hospitalized geriatric
patients. In: Klein, D.F. and Gittelman-Klein,
Rachel (eds.): Progress in Psychiatric Treatment.

Haloperidol and the butyrophenones. In: Simpson,
L.L. (ed.): Drug Treatment of Mental Disorders.

A comparative study with pipothiazine palmitate and
fluphena-zine enanthate in the treatment of
schizophrenic patients. Curr. Ther. Res., 18:585-
589, 1975.

Comprehensive clinical studies with thiothixene.

310. Ban, T.A.
Nicotinic acid in the treatment of schizophrenias:
practical and theoretical considerations.

311. Lehmann, H.E. and Ban, T.A.
Central nervous system stimulants and anabolic
substances in geropsychiatric therapy. Psychopharm.

312. Ban, T.A.
Clinical psychopharmacology and psychiatry. Dis.
313. Lehmann, H.E. and Ban, T.A.

314. Ban, T.A.

315. Ban, T.A.

316. Ban, T.A.


318. Lehmann, H.E. and Ban, T.A.

319. Ban, T.A.

320. Lehmann, H.E. and Ban, T.A.

321. Lehmann, H.E. and Ban, T.A.
322. Pecknold J.C., Ban, T.A. and Lehmann, H.E.

323. Amin, M.M., Ban, T.A., Lehmann, H.E. and Clark, R.F.


328. Pecknold, J.C., Amin, M.M., Ban, T.A. and Orbach, Lenora

Systematic clinical studies with clomipramine in
depressed psychiatric patients - IV. A summary

331. Galvan, L., Torres, A., Nietto, D., Ban, T.A. and Climan, M.
Clomacran in the treatment of schizophrenic patients
- a comparison of two assessment methods.

332. Imaz, F., Ban, T.A., Lehmann, H.E., Nair, N.P.V. and Clark,
R.F.
Butaclamol in the treatment of schizophrenic
patients - a comparison of two assessment methods.

333. Deutsch, Mina, Nair, N.P.V., Saarma, J., Ban, T.A., Lehmann,
H.E., Clark, R.F. and Schwartz, G.
Penfluridol in the treatment of schizophrenia;
Clinical and psychometric findings. Psychopharm.

334. Navarro-Ruiz, J.F., Vergara, L., Deutsch, Mina, Ban, T.A.,
Lehmann, H.E., Kachanoff, R., Nair, N.P.V. and Clark, R.F.
A comparative study of thiothixene and
chlorpromazine in chronic schizophrenic patients:
Application of a specific psychometric test battery.

335. Putzolu, Sofia, Pecknold, J.C., Baiocchi, L., Ban, T.A.,
Lehmann, H.E. and Stewart, J.A.
Clinical and biochemical studies II. Blood levels
and therapeutic responsiveness. Psychopharm. Bull.,

336. Putzolu, Sofia, Pecknold, J.C., Grad, B., Ban, T.A., Lehmann,
H.E. and Stewart, J.A.
Trazodone: Clinical and biochemical studies III.
Dexamethasone suppression test results and

337. Pecknold, J.C., Putzolu, Sofia, Ban, T.A., Lehmann, H.E. and
Stewart, J.A.
Trazodone: Clinical and biochemical studies I. An
uncontrolled clinical trial in depression.


346. Lehmann, H.E., Pecknold, J.C., Ban, T.A. and Orbach, Leora
Comprehensive clinical studies with thiothixene.

348. Ban, T.A.
Psychopharmacological treatment of schizophrenia.

349. Ban, T.A.
Psychopathology, psychopharmacology and the organic

Nicotinic acid in the treatment of schizophrenias.
Canadian Mental Health Association Collaborative
Study Progress Report II. In: Klein, D.F. and
Gittelman-Klein, Rachel (eds.): Progress in
Psychiatric Drug Treatment. Vol. 2. Brunner/Mazel,

351. Ban, T.A.
Psychopathology, psychopharmacology and the organic

352. Ban, T.A.
Pharmacotherapy of schizophrenia: A critical
evaluation. In: Advances in the Drug Therapy of
Mental Illness. World Health Organization, Geneva,
1976.

353. Nair, N.P.V., Deutsch, M., Derkevorkian, K.S., Ucha-Udabe, R.,
Ban, T.A. and Lehmann, H.E.
Doxepin and diazepam in the treatment of
hospitalized geriatric patients. Psychiatric J. of the

354. Ban, T.A. and Pecknold, J.C.
Haloperidol in the therapy of severe behavior
disorders. In: Masserman, J.H. (ed.): Current
Psychiatric Therapies. Vol. 16. Grune and Stratton,

355. Ban, T.A.
Pharmacotherapy of schizophrenia. In: Masserman,
356. Lehmann, H.E. and Ban, T.A.

357. Ban, T.A. and Pecknold, J.C.

358. Lehmann, H.E. and Ban, T.A.

359. Ban, T.A.

360. Ban, T.A.


362. Ban, T.A., Lehmann, H.E. and Deutsch, M.

363. Ban, T.A.

364. Ban, T.A., Stewart, J.A.

365. Ban, T.A.
366. St. Laurent, J., Ban, T.A. and Carle, R.
Doxepin in the treatment of neuroses: A comparative
clinical study of doxepin, chlordiazepoxide,
hydroxyzine, meprobamate and phenobarbital. Curr.

WIN 27, 147-2 in the treatment of depression. An
uncontrolled clinical study. Int.

368. Ban, T.A. and Lehmann, H.E.
Myths, theories and treatment of schizophrenia.

369. Ban, T.A. (Book Review)

370. Pecknold, J.C. and Ban, T.A.
TRH in depressive illness. Int. Pharmacopsychiat.,

371. Ban, T.A.
Perspectives in biological psychiatry - Part 3:
Schizophrenia and organic brain syndrome.

Adverse reactions: Predisposing factors. Indian J.

373. Amin, M.M., Ban, T.A. and Lehmann, H.E.
Desipramine in the treatment of depression: A
comparison of divided vs single dose administration.
Psychiat. J. of the Univ. of Ottawa, 2:117-119,
1977.

Clinical studies with maprotiline and the reversed
catecholamine hypothesis of depression. Curr. Ther.

Transmethylation hypothesis of schizophrenia:
Methionine and nicotinic acid. Int.
376. Ban, T.A.
Introduction to the Psychopharmacology of Doxepin.
Pfizer, Quebec, 1977.

Clomipramine (Anafranil) and behavior therapy in
obsessive-compulsive and phobic disorders. J. Int.

378. Amin, M.M., Ban, T.A. and Lehmann, H.E.
Introduction to the colloquium on new drugs in the
13:4-6, 1977.

379. Torres-Ruiz, A., Nieto, D. and Ban, T.A.
An uncontrolled clinical study with clomacran in
newly admitted schizophrenic patients. Psychopharm.

380. Lehmann, H.E., Ban, T.A., and Deutsch, Mina
An uncontrolled clinical study with EX 11-582A in
the treatment of chronic schizophrenic patients.

381. Ananth, J.V., Ban, T.A. and Lehmann, H.E.
An uncontrolled clinical study with thiopropazate in
the treatment of persistent dyskinesia.

382. Amin, M.M., Brahms, E., Ban, T.A. and Lehmann, H.E.
An uncontrolled clinical study with piperacetazine
in the maintenance treatment of chronic
schizophrenic patients. Psychopharm. Bull., 13:10-

383. Lehmann, H.E. and Ban, T.A.
A placebo-controlled clinical study with trazodone
in schizophrenic patients. Psychopharm. Bull.,

384. Deutsch, Mina, Ban, T.A. and Lehmann, H.E.
A standard-controlled clinical study with trazodone
in schizophrenic patients. Psychopharm. Bull.,

A standard-(trifluoperazine) controlled clinical
study with clomacran in newly admitted schizophrenic
386. Amin, M.M., Ban, T.A. and Lehmann, H.E.

387. Vergara, L., Amin, M.M. and Ban, T.A.

388. Ananth, J.V. and Ban, T.A.

389. Amin, M.M., Ban, T.A. and Lehmann, H.E.

390. Deutsch, Mina, Ananth, J.V., Ban, T.A. et al

391. Angst, J., Baird, H.L., Ban, T.A. et al

392. Ban, T.A. and Lehmann, H.E.

393. Ban, T.A.

394. Ban, T.A.
395. Ban, T.A.

396. Luchins, D., Ban, T.A. and Lehmann, H.E.

397. Ban, T.A.

398. Amin, M.M., Ban, T.A. and Lehmann, H.E.

399. Amin, M.M., Ban, T.A., Lehmann, H.E. and Khalid, R.

400. Amin, M.M., Ban, T.A., Lehmann, H.E. and Khan, P.

401. Amin, M.M., Ban, T.A. and Lehmann, H.E.

402. Amin, M.M., Ban, T.A. and Pecknold, J.C.

403. Amin, M.M., Ban, T.A., Lehmann, H.E. and Marcotte, E.

404. Smith, R., Amin, M.M. and Ban, T.A.
405. Khalid, R., Amin, M.M. and Ban, T.A.
Desipramine plasma levels and therapeutic response.

406. Ban, T.A.
The treatment of depressed geriatric patients.

Activation by thiothixene and chlorpromazine in
chronic schizophrenia: Clinical and psychometric
data. In: Peterova, E., Skoda, C. and Baudis, P.

408. Ban, T.A. and Lehmann, H.E.
Doxepin vs Diazepam: A clinical and conditioning
study. In: Peterova, E., Skoda, C. and Baudis, P.

409. Ban, T.A.
Some recent biochemical findings with possible
therapeutic implications for schizophrenia. J. of

410. Lehmann, H.E. and Ban, T.A.
Experimental approaches to psychiatric diagnosis.
In: Akiskal, H.S. and Webb, W.L. (eds.): Psychiatric
Diagnosis: Exploration of Biological Predictors.
Vol. II. Spectrum Publications., Inc., New York,
1978.

411. Ban, T.A.
Drug interactions in psychiatry. Int.

412. Ban, T.A.
Psychopharmacologie et biochimie de la
schizophrenie, contributions recentes. Medecine et

413. Ban, T.A. (Book Review)

Butaclamol in the treatment of schizophrenia. A
standard-controlled clinical trial. Int.
415. Ban, T.A.

416. Freyhan, F.A. and Ban, T.A.

417. Ban, T.A.

418. Ban, T.A.

419. Ban, T.A., Sartorius, N. and Vartanian, F.E.

420. Amin, M.M. and Ban, T.A.

421. Ban, T.A.
422. Ban, T.A. and Amin, M.M.

423. Petrie, W.M. and Ban, T.A.

424. Ban, T.A. and Petrie, W.M.


426. Ban, T.A.

427. Ban, T.A.

428. Ban, T.A.

429. Ban, T.A.


431. Ban, T.A. and Amin, M.M.

433. Ban, T.A. and Amin, M.M.

434. Ban, T.A.

435. Torres-Ruiz, M., Amin, M.M., Ban, T.A. and Pecknold, J.C.

436. Ban, T.A.


438. Ban, T.A.

439. Ban, T.A.

440. Ban, T.A.

441. Hollender, M. and Ban, T.A.
442. Ban, T.A., Vartanian, F.E., Sartorius, N. and Jablensky, A.

443. Ban, T.A.

444. Ban, T.A.

445. Ban, T.A.

446. Vergara, L., Amin, M. and Ban, T.A.

447. Wilson, W.H., Petrie, W.M. and Ban, T.A.

448. Ban, T.A. and Odejide, A.O.


450. Ragheb, M., Berney, S. and Ban, T.A.


462. Ban, T.A. (Book Review)


466. Ban, T.A.


468. Ban, T.A.

469. Ban, T.A.
470. Petrie, W.M. and Ban, T.A.

471. Libiger, J. and Ban, T.A.

472. Vartanian, F.E., Sartorius, N. and Ban, T.A.

473. Ban, T.A.


476. Ban, T.A. and Wilson, W.H.


478. Wilson, W.H., Petrie, W.M., Ban, T.A. and Barry, D.E.
479. Wilson, W.H., Petrie, W.M. and Ban, T.A.

480. Ban, T.A. (Book Review)

481. Ban, T.A. and Hollender, M.

482. Ban, T.A.

483. Ban, T.A.


485. Petrie, W.M. and Ban, T.A.

486. Kelwala, S. and Ban, T.A.

487. Petrie, W.M., Ban, T.A. and Ananth, J.V.


492. Kelwala, S. and Ban, T.A.

493. Vartanian, F.E., Odejide, A.O., Wilson, W.H. and Ban, T.A.


495. Wilson, W.H. and Ban, T.A.

496. Odejide, A.O., Ban, T.A. and Schaffer, J.D.
497. Ban, T.A.  


500. Petrie, W.M., Wilson, W.H., Jamieson, R.C. and Ban, T.A.  


502. Prakash, R., Kelwala, S. and Ban, T.A.  


504. Ragheb, M. and Ban, T.A.  

505. Guy, W. and Ban, T.A. (transls. & eds.)  

506. Ban, T.A. and McEvoy, J.P.  
507. Ban, T.A.


510. Odejide, A.O. and Ban, T.A.

511. Kato, G. and Ban, T.A.

512. Prakash, R., Kelwala, S. and Ban, T.A.

513. Ban, T.A. (Book Review)

514. Ban, T.A. and Prakash, R.

Differential therapeutic responsiveness in the
chronic schizophrenias and Leonhard's
classification. In: Ohashi, H., Nakayama, K.,
Saito, M. and Saletu, B. (eds.): The Japanese
Society of Psychiatry and Neurology, Tokyo, 1982.

517. Wilson, W.H., Higano, H., Papadatos, J., Kelwala, S. and Ban,
T.A.
Autonomic effects of fluvoxamine versus
amitriptyline, doxepin and placebo. PsycoPharm.

518. Guy, W., McEvoy, J.P., Ban, T.A. and Pate, K.
A double-blind clinical trial of mianserin versus
amitriptyline: differentiation by adverse

519. Guy, W., Ban, T.A. and Schaffer, J.D.
Differential treatment responsiveness among mildly
depressed patients. In: Clayton, P.J. and Barrett,
J.E. (eds.): Treatment of Depression: Old
Controversies and New Approaches. Raven Press, New
York, 1983.

520. Wilson, W.H. and Ban, T.A.
Distribution of Leonhard's subtypes of chronic
schizophrenia in two cultures. Can. J. Psychiatry,

521. Wilson, W.H., Higano, H., Papadatos, Y., Kelwala, S. and Ban,
T.A.
A double-blind placebo-controlled study to compare
the autonomic effects of fluvoxamine with those of
amitriptyline and doxepin in healthy volunteers.

522. Guy, W., Manov, G., Wilson, W.H., Ban, T.A., Fjetland, O.K.,
Manberg, J.P. and Dren, A.T.
Psychotropic actions of BW 234U in the treatment of
inpatient schizophrenics: A dose-range study. Drug

523. Guy, W. and Ban, T.A.
The AMDP and NCDEU/BLIPS Systems: Similarities and
differences. In: Bobon, D., Baumann, U., Angst, J.,
Helmchen, H. and Hippius, H. (eds.): The AMDP-System
in Pharmacopsychiatry. Modern Problems in
524. Ban, T.A.

525. Ban, T.A. (Book Review)

526. Guy, W., Ban, T.A., Wilson, W.H., Fjetland, O. and Pate, K.

527. Petrie, W.M. and Ban, T.A.


530. Ban, T.A.


534. Petrie, W.M. and Ban, T.A.

535. Ban, T.A.


538. Corbett, L. and Ban, T.A.

539. Ban, T.A.


542. Ban, T.A. and Guy, W.

543. Ragheb, M. and Ban, T.A.


547. Ban, T.A.

548. Ban, T.A.

549. Ban, T.A., Guy, W. and Prakash, R.

550. Ban, T.A.

551. Ban, T.A.

552. Ragheb, M. and Ban, T.A.
553. Ban, T.A. and Hovaguimian, T.

554. Ban, T.A.


556. Petrie, W.M. and Ban, T.A.

557. Petrie, W.M. and Ban, T.A.

558. Ban, T.A.


560. Guy, W. and Ban, T.A. (transls. & eds.)

561. Ban, T.A. Guy, W. and Wilson, W.H.

562. Ban, T.A. Guy, W. and Wilson, W.H.
563. Guy, W., Ban, T.A. and Wilson, W.H.
An international survey of tardive dyskinesia.

564. Ban, T.A. Guy, W. and Wilson, W.H.
Neuroleptic-induced skin pigmentation in chronic hospitalized patients.

565. Ban, T.A. and Guy, W.
Conditioning and learning in relation to disease.

566. Ban, T.A. and Ebert, M.H.

567. Ban, T.A. and Ebert, M.H.
Diagnosis and treatment of depression in the elderly: Part II. Directions in Psychiatry,

568. Ban, T.A.

569. Wilson, W.H. Ban, T.A. and Guy, W.
Pharmacotherapy of chronic hospitalized schizophrenics: Prescription practices.

570. Ban, T.A.

571. Ban, T.A.

572. Sartorius, N. and Ban, T.A.
Preface. In: Sartorius, N. and Ban, T.A. (eds.):
573. Ban, T.A.

574. Sartorius, N. and Ban, T.A. (eds.)

575. Wilson, W.H., Ban, T.A. and Guy, W.

576. Ban, T.A. and Levine, J.


578. Guy, W., Ban, T.A. and Wilson, W.H.

579. Prakash, R., Ban, T.A. and Guy, W.


581. Wilson, W.H. and Ban, T.A.

583. Wilson, W.H., Ban, T.A., Coleman, B., Vause, B. and Papadatos, J.

584. Margolin, R. and Ban, T.A.

585. Ban, T.A. (Abstract)


588. McGuigan, F.J. and Ban, T.A. (eds.)

589. McGuigan, F.J. and Ban, T.A.

591. Ban, T.A. (Abstract)


593. Ban, T.A.

594. Levine, J. and Ban, T.A.


596. Ban, T.A.

597. Ban, T.A.

598. Ban, T.A. and Ebert, M.H.
599. Ban, T.A. and Ebert, M.H.


602. Ban, T.A.

603. Ban, T.A.


605. Ban, T.A.


608. Ban, T.A.

609. Ban, T.A.

610. Ban, T.A.


612. Ban, T.A. and Lehmann, H.E.

613. Ban, T.A.

614. Ban, T.A.

615. Ban, T.A.
616. Martin, P.R., Kutcher, M., Morey, L.C., Fjetland, O., and Ban, T. A. (Abstract)


618. Gaszner, P., and Ban, T.A. (Abstract)


620. Ban, T.A.

621. Ban, T.A. and Kutcher, M.

623. Ban, T.A.  

624. Gaszner, P. and Ban, T.A. (eds.)  

625. Ban, T.A.  

626. Ban, T.A.  


628. Ban, T.A., Morey, L.C. and Santini, V.  

629. Ban, T.A.  

630. Dubini, A. and Ban, T.A.  
631. Ban, T.A.

632. Aguglia, E. and Ban, T.A. (eds.)

633. Ban, T.A.

634. Martin, P.R., Kutcher, M., Morey, L., Fjetland, O.K. and Ban, T.A.

635. Gaszner, P. and Ban, T.A.

636. Ban, T.A.

637. Ban, T.A. and Lehmann, H.E.

638. Lehmann, H.E. and Ban, T.A.

639. Ban, T.A.
640. Ban, T.A., Panzarasa, R.M., Borra, S., Del Duchetto, D. and Fjetland, O.
Cholina alphoscerato in pazienti anziani con declino cognitivo. New Trends in Clinical

641. Ban, T.A.
The CODE system in psychiatric research.

642. Ban, T.A.
Computers and psychiatric nosology with special reference to CODE-DD. Archives of Psychiatric

643. Ban, T.A.
CODE-DD Evaluation diagnostique composite des troubles dépressifs. Translated by Ferrero, F.,

644. Ban, T.A.
CODE-DD. Evaluation diagnostique composite des troubles depressifs. (Edition francaise Francois
Ferrero avec la collaboration de Marc-Antoine Crocq et Jean-Francois Dreyfus.) Editions Medecine et

645. Ban, T.A. et. al.

646. Ban, T.A. and Hippius, H. (eds.)
Psychopharmacology in Perspective: A Personal
Account by the Founders of the Collegium
Internationale Neuro-Psychopharmacologicum.

647. Ban, T.A.
Psychopharmacology and successful cerebral aging.
Clinical Neuropharmacology, 15(Supplement 1):506-

648. Ban, T.A., Panzarasa, R.M., Borra, S., Del Duchetto, D. and
Fjetland, O.
Choline alphoscerate in elderly patients with
cognitive decline due to dementing illness. New


650. Ban, T.A.


651. Ban, T.A.


654. Gaszner, P. and Ban, T.A.


655. Balter, M., Ban, T.A. and Uhlenhuth, E.H.


664. Ban, T.A.

665. Ban, T.A.

666. 602. Ban, T.A.

667. Ban, T.A.

668. Ban, T.A.

669. Ban, T.A.

670. Ban, T.A.

671. Gaszner, P. and Ban, T.A.

672. Lehmann, H.E. and Ban, T.A.

Range of medications recommended for treatment.

675. Uhlenhuth, E.H., Balter, M.B. and Ban, T.A.
Factors influencing treatment decisions in anxiety disorders.

676. Balter, M.B., Uhlenhuth, E.H. and Ban, T.A.
Factors influencing distribution of medication.

677. Ban, T.A.

678. Gaszner, P. and Ban, T.A.
BIBLIOGRAPHY FROM 1986-


BIBLIOGRAPHY 2001-2007


761. Ban, T.A., 2007. 50 years at CINP. CINP Newsletter October, p. 3